Press Releases Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.01 ^USD	+2.04%		-1.57%	-44.27%

Mar. 20	ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	CI
Mar. 07	Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	Apr. 17	AQ
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 16	BU
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	Apr. 15	BU
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 09	BU
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	Feb. 29	BU
Aurinia to Participate in Upcoming Investor Healthcare Conferences	Feb. 27	BU
Aurinia: Q4 Earnings Snapshot	Feb. 15	AQ
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	Feb. 15	BU
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024	Feb. 05	BU
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	Jan. 16	AQ
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results	Jan. 05	BU
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200	Dec. 20	BU
AURINIA PHARMACEUTICALS ANNOUNCES COLLABORATION PARTNER OTSUKA FILED NEW DRUG APPLICATION FOR LUPKYNIS IN JAPAN	Nov. 14	AQ
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan	Nov. 13	BU
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023	Nov. 07	BU
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis	Nov. 02	BU
Aurinia: Q3 Earnings Snapshot	Nov. 02	AQ
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results	Nov. 02	BU
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis	23-10-26	BU
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023	23-10-19	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Press Releases

Filters